Emulating a target trial to assess effect modification: an application to obesity in the comparative effectiveness and safety of apixaban versus warfarin in non-valvular atrial fibrillation using electronic health records

Turki M Bin Hammad, Emma Powell, Paris J Baptiste, Ian Douglas, Kevin Wing
doi: https://doi.org/10.1101/2023.10.12.23296756

Article Information

doi 
https://doi.org/10.1101/2023.10.12.23296756
History 
  • October 16, 2023.

Article Versions

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Author Information

  1. Turki M Bin Hammad1,2,*,
  2. Emma Powell2,
  3. Paris J Baptiste3,
  4. Ian Douglas2 and
  5. Kevin Wing2
  1. 1Saudi Food and Drug Authority, Riyadh, Saudi Arabia
  2. 2London School of Hygiene and Tropical Medicine, London, United Kingdom
  3. 3Queen Mary University of London, London, United Kingdom
  1. ↵*Corresponding author: Turki M Bin Hammad, tmhammad{at}sfda.gov.sa
Back to top
Posted October 16, 2023.
Download PDF

Supplementary Material

Data/Code
Email
Emulating a target trial to assess effect modification: an application to obesity in the comparative effectiveness and safety of apixaban versus warfarin in non-valvular atrial fibrillation using electronic health records
Turki M Bin Hammad, Emma Powell, Paris J Baptiste, Ian Douglas, Kevin Wing
medRxiv 2023.10.12.23296756; doi: https://doi.org/10.1101/2023.10.12.23296756
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area